The FTO (fat mass and obesity-associated) gene spans more than 400 kilobases on chromosome 16, containing nine exons and multiple functionally distinct intronic regions. The well-known FTO obesity signal resides in intron 1 (rs9939609, rs1421085), but rs1108086 sits in a completely different part of the gene — intron 8¹¹ intron 8
The eighth non-coding interval in the FTO pre-mRNA, approximately 100 kb downstream of the primary obesity cluster at chromosome 16 position 54,066,457 (GRCh38). The two regions are in very low linkage disequilibrium²² very low linkage disequilibrium
r² ≈ 0.11 in CEU populations — knowing your rs1108086 genotype tells you almost nothing about your rs9939609 genotype, making this an essentially independent locus within the same gene.

rs1108086 is in very high LD with rs1420318 (r² = 0.953 in Europeans), meaning both variants tag the same intron-8 haplotype. Carriers of the C allele at rs1108086 almost certainly carry the corresponding A allele at rs1420318, and vice versa — the two variants represent the same underlying functional signal.

The Evidence

Published evidence for this locus comes from two independent research programs. The first involves bone mineral density (BMD)³³ bone mineral density (BMD)
A measure of bone mass used to assess fracture risk and diagnose osteoporosis. A 2011 study by Guo et al. tested 141 FTO SNPs for BMD associations in two Chinese Han cohorts (N=818 and N=809) and one Caucasian cohort (N=2,286). In Chinese populations, six intron-8 FTO SNPs — all in high mutual LD and including the same haplotype block as rs1108086 — showed significant associations with hip BMD (combined p = 1.47×10⁻⁴ to 4.99×10⁻⁴), with each minor allele copy associated with increased hip BMD (β ≈ 0.015–0.025). In the Caucasian sample, the proxy variant rs1420318 showed a nominal association with spine BMD (p = 6.14×10⁻³). These associations are biologically plausible: FTO is an m6A RNA demethylase⁴⁴ m6A RNA demethylase
Removes N6-methyladenosine modifications from mRNA to regulate gene expression expressed in osteoblast-rich tissues, and body weight (modulated by the intron-1 variants) is itself a major determinant of bone loading.

The second line of evidence comes from a 2013 study by Wang et al.⁵⁵ 2013 study by Wang et al.
Genetic variants in the fat mass- and obesity-associated (FTO) gene are associated with alcohol dependence. Journal of Molecular Neuroscience that screened 167 FTO SNPs across two Caucasian samples (COGA: 660 cases/400 controls; SAGE: 623 cases/1,016 controls). rs1108086 ranked among the top three FTO SNPs associated with alcohol dependence in the SAGE cohort (p = 0.00086). This finding resonates with FTO's broader role in appetite and reward circuitry beyond adiposity alone — FTO is highly expressed in hypothalamic neurons and modulates dopaminergic signaling pathways relevant to substance use as well as eating behavior.

Both associations remain emerging⁶⁶ emerging
Neither reached genome-wide significance (p < 5×10⁻⁸), and neither has been independently replicated in multiple large cohorts at this specific locus. The BMD association was stronger in Chinese than in Caucasian populations, and the alcohol signal appeared in one of two studied cohorts.

Practical Implications

The intron-8 locus does not participate in the IRX3/IRX5 thermogenesis mechanism that drives FTO's obesity association. Carriers of the C allele at rs1108086 do not have the beige-to-white adipocyte shift associated with the intron-1 cluster. Instead, the available evidence points toward two distinct areas: bone mineral density monitoring (particularly hip and spine BMD, where the intron-8 signal was detected) and awareness of alcohol susceptibility signals. The C allele is particularly common in African and South Asian ancestry groups (~49% and ~41% respectively), compared to only ~13% in Europeans.

Interactions

rs1108086 and rs1420318 are near-redundant tags for the same intron-8 haplotype (r² = 0.953 in Europeans). They should not both generate independent compound actions — users who match one almost certainly match the other. By contrast, rs1108086 and the intron-1 obesity variants (rs9939609, rs1421085) are in low LD (r² ≈ 0.11) and can be independently inherited, representing additive effects at different functional regions of FTO.

Your body maintains thyroid hormone balance through a carefully orchestrated system of activation and inactivation. Type 1 deiodinase¹¹ Type 1 deiodinase
The DIO1 enzyme, primarily expressed in liver, kidney, and thyroid tissue (D1) is one of three enzymes that regulate this process, converting the inactive thyroid hormone T4 into active T3, while also clearing reverse T3 (rT3), an inactive metabolite. The rs11206244 variant, located in the 3' untranslated region²² 3' untranslated region
This regulatory region of the gene affects mRNA stability and protein production without changing the amino acid sequence of the DIO1 gene, influences how efficiently your body performs this conversion.

The Mechanism

This variant sits in the 3' UTR of the DIO1 gene at position 785 of the cDNA sequence.

The rs11206244 polymorphism is located in the mRNA's 3'-untranslated region of DIO1 gene , a regulatory area that can affect mRNA stability³³ mRNA stability
The 3' UTR contains signals that influence how long the mRNA molecule persists in the cell and how efficiently it is translated into protein and potentially protein production.

Carriers of the DIO1-785T allele had 3.8% higher FT4 and 14.3% higher rT3 levels, resulting in a lower T3/T4 and T3/rT3 ratio and a higher rT3/T4 ratio . This pattern is consistent with reduced D1 enzymatic activity—less efficient conversion of T4 to T3 and slower clearance of rT3.

The exact molecular mechanism remains under investigation.

As both SNPs are located in the 3'-UTR, it has been speculated whether the mRNA stability would be compromised or affect mRNA folding, which is necessary for the incorporation of Sec in the catalytic center of the protein . D1 is a selenoprotein containing the rare amino acid selenocysteine at its active site, and proper mRNA folding is essential for its incorporation.

The Evidence

Multiple large studies have consistently replicated the association between rs11206244 and thyroid hormone levels. A landmark study in healthy Danish twins⁴⁴ A landmark study in healthy Danish twins
van der Deure et al. The effect of genetic variation in the type 1 deiodinase gene on the interindividual variation in serum thyroid hormone levels. Clinical Endocrinology 2009 with 1,192 participants found that carriers of the D1-785T allele had 3.8% higher FT4 and 14.3% higher rT3 levels, resulting in a lower T3/T4 and T3/rT3 ratio and a higher rT3/T4 ratio, and this polymorphism explained 0.87% and 1.79%, respectively, of the variation in serum FT4 and rT3 . Importantly, TSH levels remained unaffected, suggesting the body compensates through feedback mechanisms.

A comprehensive study by Panicker et al.⁵⁵ A comprehensive study by Panicker et al.
Panicker et al. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. Journal of Clinical Endocrinology and Metabolism 2008 examined deiodinase gene variants in multiple cohorts and two SNPs in the DIO1 gene, rs2235544 and rs11206244, were associated with fT3/fT4 ratio at P < 0.01 . The rs11206244 and rs2235544 variants are in linkage disequilibrium⁶⁶ linkage disequilibrium
These genetic variants tend to be inherited together, though rs2235544 appears to be the primary driver of the association (r² = 0.41).

Clinically, the tightly linked rs11206244T and rs2235544A alleles have been associated with lower enzymatic activity, and carriers of the variant rs11206244T and rs2235544A alleles show reduced serum concentrations of free T3 and higher concentrations of free T4 and free rT3, but no effect on serum TSH concentration .

An interesting study on antidepressant response⁷⁷ An interesting study on antidepressant response
Cooper-Kazaz et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. American Journal of Psychiatry 2009 found that

DIO1-758T allele carriers had enhanced response to T3 supplementation with sertraline, with HRSD-21 scores declining by 68.7% over 8 weeks compared to 42.9% among non-carriers , suggesting that T carriers may benefit more from T3 supplementation.

Practical Implications

The clinical significance of this variant is nuanced. Multiple studies examining levothyroxine (T4) dose requirements in hypothyroid patients have found no significant association with polymorphisms in genes encoding the D1 and D2 enzymes, namely rs11206244 and rs2235544 in DIO1 .

The rs11206244 (C785T) SNP of DIO1 gene has no impact on the T3 and T4 hormones levels, and could have no contribution to the therapeutic response to LT4 in some populations.

However, the variant does affect thyroid hormone ratios.

Both TSH and rT3 were elevated in the carriers of T allele, though there were no significant differences in T3, T4 hormones among the three groups .

This SNP could have an impact on controlling the levels of rT3, and the effect may be more accurately reflected by the molar ratios of T3/rT3 and rT3/T4 than by the blood thyroid hormone levels .

This means that if you carry the T allele and are on thyroid hormone replacement, you may have normal TSH but still feel suboptimal if your T3/T4 ratio is low. Some patients with the T allele variant may benefit from combination T4/T3 therapy rather than T4 monotherapy, though this should be individualized and monitored by a healthcare provider.

Interactions

This variant is in moderate linkage disequilibrium with rs2235544 (another DIO1 variant), and the two tend to be inherited together. The combination of DIO1 variants may have compound effects on thyroid hormone metabolism. Additionally, other deiodinase genes (DIO2, DIO3) and thyroid hormone transporter genes can influence overall thyroid hormone status, and genetic testing across multiple loci may provide a more complete picture for individuals with persistent symptoms despite thyroid hormone replacement.

Every day your cells accumulate thousands of DNA single-strand breaks from oxidative stress, replication errors, and environmental exposures. PARP1 (Poly ADP-Ribose Polymerase 1) is the enzyme that detects these breaks and coordinates their repair — and it consumes NAD+ as fuel for every repair event it performs. The Val762Ala variant at rs1136410 reduces PARP1 enzymatic activity by roughly 40%, placing it directly at the intersection of two fundamental aging processes: DNA damage accumulation¹¹ DNA damage accumulation
unrepaired breaks that accumulate with age and NAD+ depletion²² NAD+ depletion
NAD+ levels fall 40–60% between age 20 and 60 in humans.

The Mechanism

PARP1 sits in the sixth helix of its catalytic domain, where valine at position 762 forms part of the NAD+-binding pocket. The Val→Ala substitution introduces a smaller side chain that increases the Michaelis constant (Km)³³ Michaelis constant (Km)
a measure of substrate affinity — higher Km means lower affinity for NAD+ for NAD+ binding. As a result, Ala762-PARP1 requires higher NAD+ concentrations to achieve the same catalytic output.

The in vitro characterization is precise: Wang et al. 2007⁴⁴ Wang et al. 2007 expressed both Val762 and Ala762 PARP1 recombinantly and measured activity directly. The Ala762 protein retains only 57.2% of the auto-poly(ADP-ribosyl)ation activity and 61.9% of the trans-poly(ADP-ribosyl)ation activity (on histone H1) of the Val762 protein. This is not a trivial reduction — halved repair capacity means slower response to DNA strand breaks and potentially more unrepaired lesions per cell division.

There is a crucial NAD+ feedback loop here. Normally, PARP1 consumes NAD+ during repair; the Ala762 variant needs more NAD+ to achieve equivalent repair throughput. Simultaneously, NAD+ levels decline with age due to PARP1 overactivation (from accumulating DNA damage), CD38 accumulation, and reduced biosynthesis. For Ala762 carriers, this age-related NAD+ decline creates an especially adverse environment: the enzyme is already less efficient per molecule of NAD+ consumed, and there is progressively less NAD+ available as the decades pass.

PARP1 also competes directly with SIRT1⁵⁵ SIRT1
a longevity-associated deacetylase enzyme that requires NAD+ and regulates metabolism, inflammation, and epigenetic aging for the same intracellular NAD+ pool. In PARP1-knockout mice, NAD+ levels rise, SIRT1 activity increases, and metabolic health improves — phenocopying the benefits of sirtuin activation.

The Evidence

The functional consequence of reduced PARP1 activity is measurable in humans, not just in test tubes. Associations of PARP-1 variant rs1136410 with PARP activities, oxidative DNA damage, and the risk of age-related cataract⁶⁶ Associations of PARP-1 variant rs1136410 with PARP activities, oxidative DNA damage, and the risk of age-related cataract
Cui NH et al., Gene 2017 measured PARP activity directly in blood cells of 2,055 Chinese Han participants and found that G-allele carriers (AG and GG genotypes) had significantly lower PARP activity and higher levels of 8-OHdG — a direct biomarker of oxidative DNA damage — compared to AA individuals. Critically, this translated to a measurable disease outcome: an adjusted OR of 1.42 (P=0.001) for age-related cataract, a condition driven by accumulated oxidative DNA damage in the lens.

The cancer risk data paints a complex but interpretable picture. A meta-analysis of 43 studies encompassing 17,351 cases and 22,401 controls⁷⁷ A meta-analysis of 43 studies encompassing 17,351 cases and 22,401 controls
Hua RX et al., PLoS One 2014 found no overall cancer risk increase globally, but significant cancer-type specificity: gastric cancer risk increased significantly in Ala carriers (OR 1.56 for homozygous model), while brain tumor risk paradoxically decreased (OR 0.77). In Asian populations (18 studies), Ala carriers showed consistently elevated overall cancer risk (OR 1.12–1.23). A subsequent East Asian focused meta-analysis of 24 studies (8,926 cases, 15,295 controls) confirmed these findings⁸⁸ confirmed these findings with homozygous Ala/Ala carriers showing OR 1.19 for overall cancer.

The cancer risk paradox — increased gastric cancer but decreased brain tumor risk — is not fully explained but may reflect the dual nature of PARP1 in cancer: reduced repair capacity increases mutation rates and genomic instability (pro-tumorigenic), while reduced poly(ADP-ribosyl)ation may also impair certain inflammatory signaling and cell survival pathways (potentially tumor-suppressive in specific cancer contexts).

Centenarian studies provide longevity context. Mangerich & Bürkle, Oxidative Medicine and Cellular Longevity 2012⁹⁹ Mangerich & Bürkle, Oxidative Medicine and Cellular Longevity 2012 reviewed evidence showing that poly(ADP-ribosyl)ation capacity correlates strongly with maximum lifespan across 13 mammalian species, and that human centenarians display significantly higher PARP activity than average-age populations — comparable to young healthy adults. This suggests that maintaining high PARP1 function throughout life is a feature of exceptional longevity, not just a marker of it. The Val762Ala variant, by reducing PARP1 function, may represent a genetic headwind against this pattern.

Practical Actions

The clearest actionable implication of Val762Ala is the NAD+ requirement. The Ala762 enzyme has higher Km for NAD+ — it needs more NAD+ to do the same amount of repair work. Supplementing with NAD+ precursors can raise intracellular NAD+ levels, potentially compensating for the reduced enzyme affinity. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) both raise blood and tissue NAD+ levels in human trials. In mouse studies, NMN treatment broke DBC1-PARP1 inhibitory complexes in aged mice and restored PARP activity to youthful levels¹⁰¹⁰ NMN treatment broke DBC1-PARP1 inhibitory complexes in aged mice and restored PARP activity to youthful levels
Mendelsohn & Larrick, Rejuvenation Research 2017.

Monitoring oxidative DNA damage biomarkers (urinary or blood 8-OHdG) provides direct feedback on whether DNA repair is keeping pace with damage accumulation — a particularly meaningful metric for Ala762 carriers given the demonstrated link between this genotype and elevated 8-OHdG.

Interactions

PARP1 operates within a larger DNA repair and NAD+ metabolism network. The related SNP rs3219145 in PARP1 (affecting mRNA stability and expression levels) can compound with Val762Ala: if total PARP1 protein is also reduced, the already-less-active Ala762 enzyme has less overall repair capacity. Similarly, rs2802292 in FOXO3 — a longevity-associated transcription factor that regulates oxidative stress response — is relevant because FOXO3 upregulates antioxidant defenses that reduce the DNA damage burden on PARP1 in the first place.

For individuals carrying both Val762Ala and variants in SIRT1 regulators, the NAD+ competition between PARP1 and sirtuins may be especially consequential. With reduced PARP1 efficiency requiring more NAD+ per repair event, and age-related NAD+ decline proceeding normally, sirtuin activity may be disproportionately compromised — a compound effect worthy of a combined supplementation strategy targeting NAD+ restoration.

Every autumn, rhinovirus C (RV-C) tears through daycares and schools, triggering wheezing episodes that send hundreds of thousands of children to emergency departments. Unlike rhinovirus A and B — which use ICAM-1 and LDLR as cell-entry receptors — RV-C cannot infect a cell unless that cell displays CDHR3 (cadherin-related family member 3)¹¹ CDHR3 (cadherin-related family member 3)
A transmembrane protein expressed on airway epithelial cells, belonging to the cadherin superfamily of calcium-dependent adhesion proteins; CDHR3 was identified as the rhinovirus C receptor in 2015 on its surface. Variants in the CDHR3 gene that alter receptor activity or expression therefore directly shape how efficiently RV-C can enter and replicate in the airway epithelium.

The rs114947103 variant (T>C, chromosome 7, position 106018481) is an intronic SNP located 476 base pairs downstream of the well-characterized C529Y coding variant (rs6967330). The two variants share almost identical population allele frequencies — approximately 21% for the C allele of rs114947103 and approximately 18–20% for the A allele of rs6967330 across European populations — consistent with high linkage disequilibrium. Carrying the rs114947103 C allele therefore tags the rs6967330 Y529 haplotype, which confers substantially increased RV-C receptor activity.

The Mechanism

The biological driver at this locus is the Y529 protein variant encoded by rs6967330: a cysteine-to-tyrosine change at position 529 of CDHR3. The Y529 form of the receptor binds rhinovirus C virions at roughly 10-fold higher efficiency than the common C529 form²² 10-fold higher efficiency than the common C529 form
Measured in HeLa cells stably transfected with CDHR3-Y529 vs. CDHR3-C529; both binding assays and progeny yield assays showed approximately 10-fold differences. The receptor appears to be expressed in greater amounts on the surface of airway epithelial cells in carriers of the Y529 haplotype, compounding the higher intrinsic binding affinity.

Because rs114947103 is intronic (within an intron of CDHR3 transcript variants 1 and 2, with a low CADD score of 0.894 and low evolutionary conservation), the variant itself is unlikely to be the functional change. It serves as a genomic tag for the Y529 haplotype: when population studies report associations with RV-C illness at the rs114947103 locus, they are capturing the effect of the nearby C529Y variant, which travels on the same chromosome segment.

The Evidence

The landmark 2015 study by Bochkov et al.³³ 2015 study by Bochkov et al.
Bochkov YA et al. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. PNAS 2015;112(17):5485-5490 identified CDHR3 as the rhinovirus C receptor and established that the Y529 variant dramatically amplifies receptor function. This resolved a decade-long mystery: why GWAS studies consistently found association between rs6967330 and childhood asthma hospitalizations, even though the gene was not obviously immune-related.

Bønnelykke et al. 2018⁴⁴ Bønnelykke et al. 2018
Bønnelykke K et al. Cadherin-related Family Member 3 Genetics and Rhinovirus C Respiratory Illnesses. Am J Respir Crit Care Med 2018;197(5):589-594 prospectively tracked respiratory illness episodes in two independent birth cohorts (COPSAC2010 and COAST). The CDHR3 risk allele was specifically associated with rhinovirus C illnesses (combined IRR=1.51, 95% CI 1.13–2.02, p=0.006) but showed no association with non-RV-C viral infections (IRR=1.07, p=0.37). This pathogen specificity — the genotype predicts RV-C illness but not influenza or RSV — is direct evidence that the association operates through the receptor mechanism rather than through a general immune susceptibility pathway.

In Chinese preschool and school-age children, Leung et al. 2020⁵⁵ Leung et al. 2020
Leung TF et al. Cadherin-related family member 3 gene impacts childhood asthma in Chinese children. Pediatr Allergy Immunol 2020;31(2):133-142 replicated the association: rs6967330 linked to current wheeze in preschoolers (OR=1.63) and to school-age asthma (OR=1.32). A haplotype spanning rs4730125, rs6967330, and rs408223 (a panel of CDHR3 tagging SNPs that likely includes rs114947103-correlated variants) was associated with both wheezing and asthma, confirming that the broader CDHR3 haplotype block captures the susceptibility signal across populations.

Shigemasa et al. 2020⁶⁶ Shigemasa et al. 2020
Shigemasa R et al. Genetic impact of CDHR3 on the adult onset of asthma and COPD. Clin Exp Allergy 2020;50(11):1223-1229 extended the observation to adults: in a decade-long longitudinal study of 1,523 healthy adults, the CDHR3 risk allele elevated asthma and COPD development specifically in atopic individuals, suggesting the virus-driven wheezing mechanism established in childhood persists as a risk factor into adult life.

Practical Actions

For adults, the CDHR3 haplotype matters most in the context of respiratory virus exposures. RV-C infection is essentially unavoidable across a lifetime, but the severity of individual episodes — and the likelihood that those episodes drive airway remodeling toward asthma — is influenced by viral load, exposure timing, and the immune context at the time of infection. High-efficiency CDHR3 receptors mean more virus enters more cells per exposure event.

In children and in adults who are atopic (with allergic sensitization), the risk is most actionable: RV-C wheezing episodes are the primary driver of asthma exacerbations, and preventing severe episodes during early childhood windows when airways are still developing reduces the cumulative injury that contributes to persistent asthma.

Interactions

This variant's effect operates through the rs6967330-Y529 haplotype. The functional biology is thus tightly linked to that coding variant; the two cannot be independently analyzed in most real-world genetic datasets and should be considered as co-tracking markers for elevated CDHR3 receptor activity.

The susceptibility this variant captures is specifically rhinovirus C — distinct from broader innate antiviral pathways governed by TLR3 (rs3775291) or IFITM3 (rs12252). Carriers of both a CDHR3 risk haplotype and a TLR3 hypomorphic allele would face compounded risk: higher viral entry efficiency at the epithelial surface combined with blunted interferon signaling once infection is established.

Inside every follicle in the ovary, a delicate balance of kinase activity determines whether a dormant primordial oocyte survives or is irreversibly lost. BRSK1 — BR serine/threonine kinase 1 — is one of the molecular timekeepers in this system. Variants in BRSK1 are among the most robustly replicated genetic determinants of how long ovarian function is maintained, with population-level effects on menopause timing and individual-level effects on ovarian reserve measurable years before menopause arrives.

The Mechanism

BRSK1 is an AMP-activated protein kinase (AMPK)-related kinase¹¹ AMP-activated protein kinase (AMPK)-related kinase
Member of the AMPK superfamily, activated by the upstream kinase LKB1 via phosphorylation of Thr189 in the activation loop that is expressed at highest levels in neurons but also detectably in the ovary, pancreas, and other tissues. Its primary known functions are neuronal polarization, centrosome duplication, and — critically for ovarian biology — acting as a DNA damage checkpoint²² acting as a DNA damage checkpoint
BRSK1 phosphorylates WEE1, stabilizing it and thereby inhibiting CDK1 to prevent damaged cells from entering mitosis.

This DNA damage checkpoint role explains BRSK1's grip on the ovarian clock. Primordial follicles are kept dormant partly through active checkpoint signaling. When DNA damage occurs — whether from endogenous reactive oxygen species, replication errors, or exogenous exposures such as alkylating chemotherapy — BRSK1 participates in the decision of whether a follicle is repaired and preserved or marked for apoptotic elimination. Reduced BRSK1 checkpoint efficiency accelerates follicle loss.

The upstream activator of BRSK1, LKB1, also links it to energy sensing through the AMPK pathway. Deletion of LKB1 from mouse oocytes causes premature activation of the entire primordial follicle pool³³ causes premature activation of the entire primordial follicle pool
STK11/LKB1 deletion in oocytes leads to premature ovarian failure in mice, consistent with a model where the LKB1–BRSK1 axis maintains follicle quiescence.

rs1172816 is an intronic variant that sits in the same high-LD block as the functionally studied BRSK1 SNPs rs1172822 and rs11668344 (r²=0.88 between the latter two), and serves as a proxy marker for the same functional region.

The Evidence

The foundational discovery came from a GWAS of 2,979 European women⁴⁴ GWAS of 2,979 European women
Stolk et al. 2009 Nature Genetics GWAS identifying six loci for age at natural menopause including 19q13.4/BRSK1, which identified rs1172822 (19q13.4/BRSK1) with a per-T-allele effect of −0.4 years (P=6.3×10⁻¹¹) — one of the strongest-signal loci for menopause timing at the time. The locus has since been replicated across European, Chinese, and multi-ethnic cohorts.

The Chinese replication study linked the T allele to reduced serum AMH⁵⁵ linked the T allele to reduced serum AMH
He et al. 2013 PLOS One evaluating GWAS-identified SNPs for ANM in Chinese women (OR 3.15 for lowest-AMH tertile, P=0.008), a direct ovarian reserve measurement that precedes menopause by years to decades — connecting the GWAS signal to a practical biomarker of current fertility.

The most mechanistically informative study examined 1,141 female childhood cancer survivors⁶⁶ 1,141 female childhood cancer survivors
van Dorp et al. 2021 HR meta-analysis of three independent cohorts. Among those treated with high-dose alkylating agents (cyclophosphamide equivalent dose ≥8,000 mg/m²), the G allele of the LD-linked rs11668344 was associated with OR 5.00 for AG (95% CI 3.27–7.63) and OR 6.53 for GG (95% CI 2.36–18.05) for reduced ovarian function (P=3.0×10⁻⁴). The interpretation: reduced BRSK1 checkpoint efficiency makes follicles more vulnerable to DNA damage.

Practical Actions

The T allele's effect on ovarian reserve is modest (−0.4 years per allele in population terms) but becomes clinically meaningful when combined with lifestyle exposures that impose DNA damage on oocytes — smoking, alcohol, radiation, and environmental toxicants. Limiting these exposures directly addresses the BRSK1 mechanism. Serum AMH testing provides an individualized measure of current ovarian reserve and gives years of advance notice before fertility declines. For women planning delayed childbearing or facing chemotherapy, baseline AMH and antral follicle count establish a reference.

Anti-oxidant micronutrients — particularly CoQ10 (as ubiquinol), vitamin E, and N-acetylcysteine — support mitochondrial function in oocytes and reduce endogenous oxidative DNA damage, directly relevant to a variant that reduces checkpoint efficiency for DNA-damaged follicles.

Interactions

BRSK1 acts downstream of LKB1 (STK11), and upstream through WEE1 phosphorylation. Variants that increase endogenous DNA damage burden — such as null alleles in detoxification genes (GSTM1, GSTT1) or oxidative stress variants (SOD2) — could interact with reduced BRSK1 checkpoint efficiency to compound follicle attrition. These interactions have not been formally studied for rs1172816, but the pathway logic is biologically consistent.

Inside every kidney proximal tubule cell, a small adaptor protein called DAB2 (Disabled-2) serves as a molecular traffic controller — guiding megalin and cubilin receptors through the endocytic pathway that recovers albumin, vitamins, and hormones from filtered urine. DAB2¹¹ DAB2
Disabled-2, encoded by the DAB2 gene on chromosome 5p13.1 is essential for normal proximal tubule reabsorption. The rs11959928 variant sits in an intronic regulatory region of the DAB2 gene and alters how much DAB2 protein tubule cells produce — with downstream consequences for kidney fibrosis and chronic kidney disease (CKD).

The rs11959928 variant lies within a kidney-specific enhancer element that is active in proximal tubular cells but silent in other tissues. The A allele (risk allele) increases the transcriptional activity of this enhancer, driving higher DAB2 mRNA levels in tubules.

The clinical consequence of elevated DAB2 comes from a second, less well-known role: DAB2 is a co-activator of TGF-β²² TGF-β
transforming growth factor beta, the master driver of organ fibrosis signaling. DAB2 promotes clathrin-mediated recycling of TGF-β receptor II, protecting it from lysosomal degradation and sustaining SMAD2/SMAD3 phosphorylation. The result is a fibrotic feedback loop: more DAB2 → more TGF-β receptor at the cell surface → more SMAD signaling → more collagen and fibronectin deposition → interstitial scarring → reduced glomerular filtration rate.

This tubule-specific mechanism explains why the eQTL effect of rs11959928 on DAB2 is detectable only in kidney tubule tissue (not glomerulus or 44 other tissues in GTEx) — the enhancer is tissue-restricted³³ the enhancer is tissue-restricted.

The original discovery came from the CKDGen consortium's 2010 meta-analysis of 67,093 Europeans, which identified the DAB2 locus among 13 new genome-wide significant hits for eGFR and CKD risk. Köttgen et al., Nature Genetics, 2010⁴⁴ Köttgen et al., Nature Genetics, 2010

Functional follow-up confirmed the biology. Tubular expression of DAB2 and its neighbor FYB both correlated strongly with eGFR in human kidney biopsy samples (DAB2 P=3.68×10⁻⁵; FYB P=3×10⁻⁸ in tubule-enriched samples), while neither showed a glomerular eQTL — pointing to a purely tubulointerstitial mechanism. Flaquer et al. / Functional Genomic Annotation study, JASN 2015⁵⁵ Flaquer et al. / Functional Genomic Annotation study, JASN 2015

The causal link was pinned down in a 2018 Nature Medicine study. Tubule-specific eQTL mapping across 121 human kidney samples found that the A risk allele of rs11959928 raises tubular DAB2 expression with an effect size of β=0.566 (P=3.52×10⁻⁶), and colocalization analysis gave PP_H4=0.938 — very strong evidence that the GWAS hit and the eQTL share the same causal variant. Crucially, mice with tubule-restricted Dab2 deletion were significantly protected from interstitial fibrosis after both folic-acid nephropathy and ureteral obstruction injury models, confirming the causal direction. Qiu et al., Nature Medicine, 2018⁶⁶ Qiu et al., Nature Medicine, 2018

Prospective data extend the finding: the DAB2 locus predicts incident CKD independently of baseline eGFR, suggesting the variant influences disease progression rather than merely reflecting starting kidney function. Grams et al., PLOS Genetics, 2013⁷⁷ Grams et al., PLOS Genetics, 2013

A sex-stratified analysis in a Central European CKD cohort found the A allele's association with prevalent CKD was significant in males under both additive and dominant models, with homozygous AA males showing more than a two-fold increase in CKD prevalence compared to TT homozygotes.

The A allele frequency varies substantially by ancestry: ~44% in Europeans, ~32% in Africans, and only ~17% in East Asians — so the population-attributable risk differs markedly across ethnic groups.

There is no pharmacological intervention that directly targets DAB2, but several evidence-based strategies modify TGF-β-driven renal fibrosis through upstream modulation:

• Blood pressure control is the single most modifiable risk factor for eGFR decline. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) reduce TGF-β signaling in the kidney and slow CKD progression in proteinuric patients.
• Dietary protein moderation (0.6–0.8 g/kg/day rather than high-protein diets) reduces glomerular hyperfiltration and tubular TGF-β load.
• Sodium restriction (< 2 g/day sodium; < 5 g/day salt) reduces systemic and intraglomerular pressure, a direct upstream driver of tubular TGF-β activation.
• eGFR and urine albumin-creatinine ratio (uACR) monitoring allows early detection of CKD progression, when RAAS-based interventions are most effective.
• Avoiding nephrotoxic exposures — NSAIDs, contrast dye, aminoglycosides, and heavy metal exposures — is especially important for AA genotype carriers, whose tubular reserve may be more vulnerable.

The DAB2 locus operates in the same tubulointerstitial fibrosis pathway as UMOD (rs4293393) and SHROOM3 (rs17319721), two other well-replicated CKD GWAS loci. While no compound-genotype study has formally quantified the combined effect of rs11959928 with UMOD or SHROOM3 variants, carriers of multiple risk alleles across these loci are likely to experience additive acceleration of CKD progression through convergent fibrotic mechanisms.

DACH1 (rs626277) and PRKAG2 (rs7805747), two adjacent CKD GWAS hits on other chromosomes, were found to associate with CKD in the same sex-stratified cohort study as rs11959928, suggesting these loci may jointly explain CKD risk especially in male patients.

Every time you go more than a few hours without eating, your body shifts from burning dietary glucose to burning stored fat. This switch depends on fatty acid oxidation¹¹ fatty acid oxidation
the mitochondrial process of breaking down fatty acids into acetyl-CoA for energy production, generating ketone bodies as fuel for the brain and heart — and medium-chain fatty acids (C6–C12 carbon chains) are a major energy source during that transition. The enzyme that catalyzes their first oxidation step is MCAD²² MCAD
Medium-Chain Acyl-CoA Dehydrogenase, encoded by the ACADM gene on chromosome 1p31, a homotetramer assembled inside the mitochondrial matrix. Without functional MCAD, medium-chain fatty acids accumulate as acylcarnitines in blood and urine, ketones cannot be generated adequately, and blood glucose can drop to dangerous levels during fasting or illness.

The c.199T>C variant (rs121434280) causes a tyrosine-to-histidine substitution at position 67 of the MCAD protein (p.Tyr67His, also historically noted as Y42H using mature-protein numbering). This variant is listed as Pathogenic in ClinVar³³ ClinVar
VCV000003597, 2-star classification from 16 independent laboratory submissions and is referenced in OMIM⁴⁴ OMIM
Entry 607008.0011 as one of the catalogued ACADM allelic variants. Its clinical meaning, however, is substantially milder and more context-dependent than classic MCAD-deficiency mutations — making it one of the most instructive examples of how the same "pathogenic" label can span a wide spectrum of biological effect.

The Mechanism

Tyr67 sits in the N-terminal α-helical domain of MCAD and contributes to the correct folding and tetramer assembly of the enzyme. The Y67H substitution introduces a histidine residue whose altered side-chain geometry subtly destabilizes the local protein fold. At normal body temperature (37°C), the mutant protein retains substantial catalytic activity — measured in multiple independent studies at 45–91% of wild-type⁵⁵ 45–91% of wild-type
Jank JM et al. The domain-specific and temperature-dependent protein misfolding phenotype of variant medium-chain acyl-CoA dehydrogenase. PLoS One, 2014.

The critical feature of Y67H is its temperature dependence: higher temperature shifts the protein toward misfolded, aggregated conformations, progressively reducing its activity. This means that during a febrile illness — when core body temperature may reach 39–40°C — the residual MCAD activity in a Y67H carrier can drop significantly. In an individual who is compound heterozygous (carrying Y67H on one chromosome and a more disruptive mutation on the other), this fever-induced loss of the Y67H allele's residual contribution can tip the balance toward clinically meaningful MCAD insufficiency.

A landmark study on enzyme activity thresholds established⁶⁶ established
Tucci S et al. Genotype and residual enzyme activity in MCAD deficiency: Are predictions possible? J Inherit Metab Dis, 2021 that residual MCAD activity above ~30% is sufficient to prevent clinical disease. Y67H homozygotes, with activities in the 45–91% range, fall well above this threshold under normal physiological conditions. Compound heterozygotes, however, may approach the critical range during fever.

The Evidence

Newborn screening has been essential in characterizing this variant's population frequency and clinical profile. In a landmark Bavarian screening study of 524,287 neonates, Maier et al.⁷⁷ Maier et al.
Maier EM et al. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening. Hum Mutat, 2005 identified c.199T>C (Y67H) in 9 of 57 MCADD-positive newborns, with 6 of these 9 being compound heterozygous with the severe c.985A>G (K329E) allele. None of the Y67H homozygotes developed clinical MCADD.

A separate functional analysis by Sturm et al.⁸⁸ Sturm et al.
Sturm M et al. Functional effects of different MCAD genotypes and identification of asymptomatic variants. PLoS One, 2012 measured octanoyl-CoA oxidation rates in lymphocytes from 65 newborns and found that individuals carrying c.199T>C showed residual activities of 31–60%, "clearly in the range of proven heterozygotes that do not have a risk of symptomatic disease." Based on this, the authors classified c.199T>C as likely biochemically mild when homozygous.

The population carrier frequency for Y67H is approximately 1 in 500⁹⁹ population carrier frequency for Y67H is approximately 1 in 500
O'Reilly L et al. The Y42H mutation in medium-chain acyl-CoA dehydrogenase, which is prevalent in babies identified by MS/MS-based newborn screening, is temperature sensitive. Eur J Biochem, 2004, making it one of the three most prevalent pathogenic ACADM alleles in people of European ancestry. Its global gnomAD allele frequency is ~0.05% (roughly 140/282,000 alleles).

Practical Actions

For individuals homozygous for Y67H, current evidence suggests that clinical MCAD deficiency is unlikely. However, because body temperature during illness can meaningfully reduce Y67H MCAD activity, it is prudent for homozygotes to know that febrile illnesses are a trigger for caution — early antipyretic treatment and maintaining caloric intake during fever episodes are advisable.

For heterozygous carriers, the single C allele produces no clinical risk — one functional ACADM copy is sufficient. The primary concern for carriers is reproductive: if both parents carry pathogenic ACADM variants (whether Y67H or other mutations), each pregnancy has a 25% probability of compound heterozygosity. Because compound heterozygotes pairing Y67H with a more severe allele (especially K329E, rs77931234) may have clinically significant MCAD deficiency requiring dietary and emergency management, carrier couples should discuss this with a genetic counselor before or during pregnancy.

Interactions

The most clinically important interaction for this variant is compound heterozygosity with rs77931234 (ACADM K329E). K329E is the most common severe MCAD allele (~67% of defective alleles in European newborns), with residual activity near zero when homozygous. Individuals who carry Y67H on one chromosome and K329E on the other have a combined MCAD activity that depends partly on the Y67H allele's temperature-sensitive contribution. At normal temperature they may have borderline-sufficient activity, but during fever the combined deficiency can become symptomatic — requiring fasting avoidance, high-glucose oral intake, and IV dextrose if unable to tolerate oral feeding. This gene-gene (allele-allele) interaction is well-documented in newborn screening literature and should be flagged to families where both alleles are identified.

Your small intestine contains a protein called ZIP4, encoded by SLC39A4, that acts as the primary gateway for absorbing dietary zinc. ZIP4 sits on the apical (luminal) surface of enterocytes in the duodenum and jejunum, where it actively transports zinc ions from food into the intestinal wall — the first step in getting zinc from your plate into your bloodstream. Without a functioning ZIP4, dietary zinc passes through the gut essentially unabsorbed, no matter how much you eat.

The Arg95Cys variant (rs121434292) is a single-letter change at position 283 of the SLC39A4 coding sequence (c.283C>T), replacing arginine with cysteine at protein position 95. This missense substitution disrupts the ZIP4 protein structure and causes acrodermatitis enteropathica¹¹ acrodermatitis enteropathica
AE: a rare inherited zinc malabsorption disorder first described in 1942. It is distinct from dietary zinc deficiency — it is a genetic inability to absorb zinc from food regardless of intake, an autosomal recessive disorder first linked to SLC39A4 in a landmark 2002 study²² a landmark 2002 study
Wang K et al. A novel member of a zinc transporter family is defective in acrodermatitis enteropathica. Am J Hum Genet, 2002.

The Mechanism

ZIP4 is not a simple channel — it is a regulated transporter that dynamically shuttles between the enterocyte membrane and intracellular compartments depending on zinc availability. When dietary zinc is plentiful, ZIP4 is endocytosed and held inside the cell; when zinc is scarce, ZIP4 moves to the apical membrane to maximize absorption. This feedback loop keeps systemic zinc levels stable across a wide range of dietary intakes.

The Arg95 residue lies within the large extracellular domain of ZIP4, which is critical for correct protein folding and membrane trafficking. Functional studies of related AE missense mutations by Wang et al. 2004³³ Wang et al. 2004
Wang F et al. Acrodermatitis enteropathica mutations affect transport activity, localization and zinc-responsive trafficking of the mouse ZIP4 zinc transporter. Hum Mol Genet, 2004 demonstrated that all tested AE-associated missense variants either abolish zinc transport activity outright or impair zinc-responsive endocytosis. Arg95Cys-type substitutions in the extracellular domain are expected to disrupt protein folding and prevent correct trafficking to the cell surface — a class of defect that effectively silences the transporter.

The Evidence

Arg95Cys was first reported by Nakano et al. 2003⁴⁴ Nakano et al. 2003
Nakano A et al. Novel SLC39A4 mutations in acrodermatitis enteropathica. J Invest Dermatol, 2003 in Japanese twins presenting with the classical AE triad of periorificial dermatitis, diarrhea, and alopecia. The twins carried Arg95Cys in compound heterozygosity with a 53-bp insertion creating a premature stop codon — a typical presentation for AE, where patients are rarely true homozygotes but instead carry two different loss-of-function alleles. The mutation was absent from 100 control chromosomes screened in the same study, supporting pathogenicity.

The variant is recorded in ClinVar as Pathogenic/Likely pathogenic (VCV000003722, 2-star review, multiple submitters, no conflicts, last evaluated January 2025). It is exceptionally rare in population databases: gnomAD exomes record only 9 heterozygous carriers among 685,748 individuals screened (allele frequency ~6.6 × 10⁻⁶), with no homozygotes identified — consistent with a highly penetrant recessive disorder causing early-onset illness in the rare individuals who inherit two loss-of-function alleles.

AE itself occurs at approximately 1 in 500,000 newborns globally, though the true incidence may be higher due to misdiagnosis as nutritional zinc deficiency or other skin conditions. Without genetic confirmation and zinc supplementation, the disorder can progress to severe immune dysfunction, growth failure, neurological complications, and historically even death. With lifelong zinc supplementation, the prognosis is excellent — clinical response typically begins within days and is essentially complete.

Practical Actions

For heterozygous carriers (AG genotype): no treatment is needed. Heterozygous carriers have one functional copy of SLC39A4 and one defective copy. The single working copy provides sufficient ZIP4 activity to maintain normal zinc absorption and serum zinc levels. Carriers are clinically unaffected. The primary significance of carrier status is reproductive risk: if both parents carry a pathogenic SLC39A4 variant, each pregnancy has a 25% chance of inheriting two defective copies and developing AE.

For homozygous or compound heterozygous individuals (AA or biallelic variants): the cornerstone of treatment is lifelong oral zinc supplementation starting at 3 mg/kg/day of elemental zinc, with most children ultimately maintained at 1-3 mg/kg/day. Zinc sulfate is the most widely used formulation; zinc gluconate and zinc acetate are alternatives for those who experience gastrointestinal irritation from sulfate. Because zinc and copper share the same absorption pathway (metallothionein induction), chronic high-dose zinc supplementation can cause copper deficiency — serum copper and zinc should both be monitored every 3-6 months, with dose adjusted to the lowest level maintaining normal serum zinc (70-120 µg/dL).

Interactions

Acrodermatitis enteropathica is caused by compound heterozygosity for two different pathogenic SLC39A4 alleles in the great majority of cases — true Arg95Cys homozygotes are rarely reported. Any individual identified as an Arg95Cys carrier who develops AE symptoms should have both SLC39A4 alleles fully sequenced to identify the second pathogenic variant, which may be a different missense, nonsense, frameshift, splice-site, or structural variant in the gene.

There are no well-documented interactions between rs121434292 and variants in other zinc transporter genes (SLC30A1-10, SLC39A1-14) that meaningfully alter clinical management for carriers. The clinical ZIP4 deficiency state in homozygotes is profound enough that other transporter variants do not compensate.

Uric acid¹¹ Uric acid
The final breakdown product of purine metabolism in humans. Unlike most mammals, humans lack uricase and cannot degrade uric acid further, so serum levels are tightly regulated by the kidney is a double-edged molecule. High levels cause gout and kidney stones; dangerously low levels, it turns out, carry their own risks. The SLC22A12 gene encodes URAT1 (Urate Transporter 1)²² URAT1 (Urate Transporter 1)
A solute carrier protein in the proximal tubule of the kidney that reabsorbs approximately 90% of filtered uric acid back into the bloodstream. Without it, uric acid spills freely into the urine, the dominant uric acid recapture protein in the kidney. The W258X variant (rs121907892) creates a premature stop codon at position 258, truncating the protein and abolishing its transport function entirely.

The result is renal hypouricemia type 1 (RHUC1)³³ renal hypouricemia type 1 (RHUC1)
A condition defined by a serum uric acid level below 2 mg/dL caused by loss of renal urate reabsorption. Most carriers are asymptomatic but have a measurably increased risk of exercise-induced acute kidney injury — a condition where the kidneys fail to hold onto uric acid, leading to serum levels as low as 0.8 mg/dL in homozygotes. This variant is almost exclusively found in East Asian populations, where it is the most common genetic cause of hypouricemia.

The Mechanism

The URAT1 transporter sits on the apical membrane of proximal tubule cells, facing the filtered urine. Under normal conditions it reabsorbs roughly 90% of urate filtered by the glomerulus. The W258X nonsense mutation — a single G→A substitution at nucleotide 774 of the SLC22A12 coding sequence — introduces a stop codon at amino acid 258, producing a truncated protein that lacks the carboxyl-terminal transmembrane domains essential for membrane targeting and transport activity. The truncated protein is not localized to the cell membrane and is functionally inert.

Toyoda et al. (2021)⁴⁴ Toyoda et al. (2021)
Toyoda Y et al. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. Rheumatology (Oxford), 2021 confirmed at the mechanistic level that W258X-truncated URAT1 is not membrane-localized and does not transport urate. Each lost copy reduces serum uric acid substantially, with heterozygotes showing intermediate values and homozygotes reaching near-zero levels.

The Evidence

Komoda et al. (2004)⁵⁵ Komoda et al. (2004)
Komoda F et al. The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia. Pediatr Nephrol, 2004 established W258X as the dominant cause of Japanese renal hypouricemia: 11 of 12 identified mutational alleles in 6 of 7 hypouricemia patients were W258X, with 5 patients homozygous and one compound heterozygous.

A cross-sectional study of 5,023 Japanese health examinees⁶⁶ cross-sectional study of 5,023 Japanese health examinees
Hamajima N et al. Serum uric acid distribution according to SLC22A12 W258X genotype in a cross-sectional study of a general Japanese population. BMC Med Genet, 2011 quantified the genotype-phenotype relationship precisely. Males with GG genotype averaged 6.2 mg/dL serum uric acid; heterozygotes (GX) averaged 3.9 mg/dL; the five GG homozygotes averaged just 0.8 mg/dL. The X allele frequency was 2.3% (95% CI: 2.1–2.7%), yielding an estimated XX homozygote prevalence of roughly 1 in 2,000 in Japanese populations.

Sakiyama et al. (2016)⁷⁷ Sakiyama et al. (2016)
Sakiyama M et al. The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep, 2016 studied 1,993 gout patients and 4,902 health examinees. W258X was absent in every single gout case. Among health examinees, males carrying one nonfunctional allele had 2.19 mg/dL lower serum uric acid than wild-type; those with two had 5.42 mg/dL lower — an effect so large it completely eliminated hyperuricemia risk (risk ratio 0.036, P = 6.7×10⁻¹⁹ in males).

The darker side of URAT1 loss emerged in studies of exercise-induced acute kidney injury (EIAKI)⁸⁸ exercise-induced acute kidney injury (EIAKI)
AKI occurring hours after intense physical exertion in people with renal hypouricemia. Believed to result from uric acid crystals precipitating in the tubules during the high urine flow and concentration spikes of exercise. Kaito et al. (2013)⁹⁹ Kaito et al. (2013)
Kaito H et al. Molecular background of urate transporter genes in patients with exercise-induced acute kidney injury. Am J Nephrol, 2013 analyzed 17 EIAKI patients: 15 carried SLC22A12 mutations (mostly W258X). All homozygous or compound heterozygous carriers had documented hypouricemia. Critically, impaired transporter function — not merely low serum uric acid — appeared to drive the AKI risk, since some heterozygous carriers with borderline uric acid levels also experienced EIAKI.

Animal evidence from a double knockout mouse model¹⁰¹⁰ double knockout mouse model
Hosoyamada M et al. Urat1-Uox double knockout mice are experimental animal models of renal hypouricemia and exercise-induced acute kidney injury. Nucleosides Nucleotides Nucleic Acids, 2016 confirmed that these mice spontaneously develop exercise-induced AKI, and that allopurinol — by reducing uric acid production upstream — provides prophylactic protection.

Practical Actions

Heterozygous carriers (AG) have intermediate serum uric acid levels — roughly 3.9 mg/dL average in males — which is well within the safe range and confers protection against gout. No specific interventions are required, but awareness of hydration needs during intense exercise is prudent.

Homozygous carriers (AA) face a different calculus. Serum uric acid below 1 mg/dL creates a real risk of exercise-induced AKI: episodes can occur with vigorous activity, typically presenting as flank pain, hematuria, and oliguria within hours of exercise. Prevention centers on avoiding dehydration, moderating intensity, and — in consultation with a nephrologist — potentially considering low-dose allopurinol as prophylaxis during high-intensity training periods.

Homozygotes should also disclose their condition before surgery or procedures involving contrast agents, as the hypouricemic kidney may be more vulnerable to additional acute insults.

Interactions

The W258X variant interacts with the companion SLC22A12 variant R90H (rs147647315), another loss-of-function allele present at low frequency in East Asian populations. Compound heterozygosity for W258X and R90H produces the same full-LOF phenotype as W258X homozygosity. A second urate transporter gene, SLC2A9 (encoding GLUT9), harbors variants that cause renal hypouricemia type 2 — these can produce overlapping phenotypes including EIAKI and should be considered in hypouricemic patients who test negative for SLC22A12 mutations.

When a blood vessel is damaged, the body must rapidly form a clot—but equally important is knowing when to stop. Protein S¹¹ Protein S
Protein S is a vitamin K-dependent anticoagulant glycoprotein synthesized primarily in the liver, endothelial cells, and megakaryocytes. It circulates both free (active, ~40%) and bound to C4b-binding protein (~60%). Only free protein S functions as an anticoagulant cofactor. is one of the body's key brakes on coagulation: it acts as an essential cofactor for activated protein C (APC)²² activated protein C (APC)
Activated protein C is a serine protease that degrades clotting factors Va and VIIIa, the two amplifiers of the coagulation cascade. Without protein S as its cofactor, APC's anticoagulant activity is severely impaired, allowing the clotting cascade to continue unchecked., facilitating the degradation of clotting factors Va and VIIIa. When protein S is reduced, the coagulation brake weakens—and blood clots can form in veins where they don't belong.

The PROS1 K196E variant (c.586A>G, NM_000313.4) is a pathogenic missense mutation replacing a positively charged lysine with a negatively charged glutamic acid at position 196 of protein S. Classified as Pathogenic in ClinVar (variation ID 13318)³³ ClinVar (variation ID 13318)
Review status: criteria provided, multiple submitters, no conflicts — a 2-star review status indicating independent clinical classification agreement for both autosomal dominant and autosomal recessive thrombophilia, and listed as OMIM allelic variant 176880.0003⁴⁴ OMIM allelic variant 176880.0003
OMIM: Online Mendelian Inheritance in Man. 176880 is the PROS1 gene entry; .0003 denotes the third catalogued pathogenic allelic variant in this gene. The variant is rare globally but notably enriched in East Asian populations — the TOMMO Japanese cohort (N=77,444) identifies the C allele at approximately 1% frequency, compared to effectively absent in European and African populations.

The Mechanism

The K196E substitution falls within the sex hormone-binding globulin (SHBG)-like domain⁵⁵ sex hormone-binding globulin (SHBG)-like domain
The SHBG-like domain (also called the laminin G-type domain) of protein S mediates its direct anticoagulant activities independent of activated protein C — including direct inhibition of factors Xa and Va and enhancement of tissue factor pathway inhibitor (TFPI) activity on the cell surface of protein S. Replacing Lys196 with Glu introduces a charge reversal in a region critical for both protein-protein interactions and for the conformational integrity of the SHBG-like domain. The functional consequence is reduced free protein S activity — heterozygous carriers typically have free protein S levels in the 40–60% of normal range (type I deficiency pattern: concordantly reduced antigen and activity).

Research from Fenclova et al., 2023⁶⁶ Fenclova et al., 2023
Fenclova T et al. Res Pract Thromb Haemost 2023;7(4):100110 — 76 patients with suspected protein S deficiency, 17 missense mutations analyzed. SHBG-region mutations showed OR 5.17 (95% CI 1.29–20.65) for thrombosis vs non-SHBG mutations, p=0.02. found that PROS1 missense mutations in the SHBG-like domain carried an independently elevated thrombotic risk compared to mutations elsewhere in the protein—suggesting the location of K196E within this domain may compound the functional impact beyond simply lowering protein S levels.

The Evidence

The most definitive population-scale data comes from Chaudhry et al., JAMA, 2025⁷⁷ Chaudhry et al., JAMA, 2025
Chaudhry SA et al. JAMA 2025;333(16):1423–1432 — N=426,436 UK Biobank participants (44,431 with plasma proteomics), N=204,006 NIH All of Us participants; 18,011 VTE cases. This study stratified PROS1 variants by functional impact score (FIS). High-impact variants (nonsense, frameshift, essential splice sites, FIS=1.0) conferred an OR of 14.01 (95% CI 6.98–27.14) for venous thromboembolism — the strongest genetic thrombosis risk estimated in a population cohort. PROS1 missense variants with FIS ≥0.7 conferred an OR of 1.977 (95% CI 1.552–2.483, p=1.95×10⁻⁷). The K196E variant's specific FIS and VTE risk in this study were not individually reported, but as a pathogenic missense variant classified by multiple clinical laboratories, it falls within the high-impact category.

Importantly, the study found no association between PROS1 variants and arterial thrombosis (myocardial infarction, peripheral artery disease, stroke), confirming protein S deficiency as a specifically venous thrombotic risk.

Lifetime risk elevation is sustained: Kaplan-Meier analysis showed VTE risk remained elevated throughout adult life for PROS1 high-impact variant carriers (log-rank p=0.0005).

Practical Actions

For K196E carriers, the core clinical actions are: confirm biochemical protein S levels, assess cumulative VTE risk given personal history and circumstances, and strategically deploy anticoagulation during high-risk periods. Protein S deficiency is particularly important to recognize before situations that independently elevate clotting risk — surgery, prolonged immobilization, pregnancy, and estrogen-containing contraceptives.

Venous thromboembolism from protein S deficiency typically presents as deep vein thrombosis (DVT) of the lower limbs or pulmonary embolism (PE), but unusual sites such as portal, mesenteric, or cerebral vein thrombosis have been documented in PROS1 variant carriers. A first unprovoked DVT or PE in a person with K196E should prompt specialist hematology evaluation and decisions about duration of anticoagulation.

Note that protein S levels fluctuate physiologically — they fall during pregnancy, with oral contraceptives, and during acute illness or warfarin therapy. Testing must be performed in the correct clinical context to avoid misinterpretation. Genetic confirmation of K196E is the most reliable long-term identifier of protein S deficiency.

Interactions

K196E acts within the broader natural anticoagulant system, which includes protein C (encoded by PROC) and antithrombin (encoded by SERPINC1). Concurrent genetic defects in two anticoagulant pathways dramatically amplify thrombotic risk — a PROS1 K196E carrier who also carries a pathogenic PROC or SERPINC1 variant, or who is heterozygous for Factor V Leiden (rs6025), faces substantially higher lifetime VTE risk than any single deficiency alone. Factor V Leiden is common (~3–8% of Europeans) and synergizes with natural anticoagulant deficiencies. Genetic testing panels that include PROC, SERPINC1, F2 prothrombin (rs1799963), and Factor V Leiden should be considered in K196E carriers.